Agios
Over the 12+ years Agios has been in existence, we have remained committed to patients first and to following the science. Our legacy is rooted in a powerful set of strengths, values and competencies. We have built on our core differentiators to make a positive difference for patients through truly differentiated therapies. This foundation will remain constant at Agios and accelerate our impact moving forward.
Total Visits
Avg. Visit Duration
Pages per Visit
Bounce Rate
Registration Date
| Month | Traffic |
|---|---|
| 2025-02 | 16.726 |
| 2025-03 | 21.116 |
| 2025-04 | 21.959 |
| Source | Traffic Share |
|---|---|
| search | 51.65% |
| direct | 36.50% |
| referrals | 6.59% |
| social | 4.05% |
| paid referrals | 0.93% |
| 0.22% |
| Region | Percentage |
|---|---|
| United States | 79.30% |
| IT | 4.28% |
| ES | 4.08% |
| United Kingdom | 3.39% |
| India | 2.42% |
| Keyword | Traffic | Volume | CPC |
|---|---|---|---|
| agios pharmaceuticals | 450 | 4,500 | $0.00 |
| agios | 958 | 9,580 | $0.21 |
| agios leadership | 21 | 210 | $0.00 |
| julian patrice agios | 0 | 0 | $0.00 |
| luspatercept talassemia | 6 | 60 | $0.00 |